Activity of trimethoprim/sulfamethoxazole plus polymyxin B against multiresistant Stenotrophomonas maltophilia

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 15, Issue 11, 1996, Pages 879-882

  Munoz J L ^a   Garcia M I ^a   Munoz S ^a   Leal, S ^a   Fajardo, M ^a   Garcia Rodriguez J A ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; IMIPENEM; PIPERACILLIN; POLYMYXIN B; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; STENOTROPHOMONAS MALTOPHILIA;

EID: 0029775938     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01691222     Document Type: Article

References (14)

1. Holmes B, Lapage SP, Easterling BG: Distribution in clinical material and identification of Pseudomonas maltophilia. Journal of Clinical Pathology 1979, 32: 62-72.
2. Elting LS, Khardori N, Bodey GP, Fainstein V: Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infection Control and Hospital Epidemiology 1990, 11: 134-138.
3. Khardori N, Elting L, Wong E, Schable B, Bodey GP: Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Reviews of Infectious Diseases 1990, 12: 997-1003.
4. Garcia-Rodríguez JA, Garcia Sanchez JE, Garcia Garcia MI, Garcia Sanchez E; Muñoz Bellido JL: Antibiotic susceptibility profile of Xanthomonas maltophilia in vitro activity of β-lactam/β-lactamase inhibitor combinations. Diagnostic Microbiology and Infectious Disease 1991, 14: 239-243.
5. Bonfiglio G, Livermore DM: Effect of media composition on the susceptibility of Xanthomonas maltophilia to β-lactam antibiotics. Journal of Antimicrobial Chemotherapy 1991, 28: 837-842.
6. Pankuch GA, Jacobs MR, Rittenhouse SF, Appelbaum PC: Susceptibilities of 123 strains of Xanthomonas maltophilia to eight β-lactams (including β-lactam/β-lactamase inhibitor combinations) and ciprofloxacin tested by five methods. Antimicrobial Agents and Chemotherapy 1994, 38: 2317-2333.
7. Neu HC, Saha G, Chin NX: Resistance of Xanthomonas maltophilia to antibiotics and the effect of beta-lactamase inhibitors. Diagnostic Microbiology and Infectious Disease 1989, 12: 283-285.
8. Felegie TP, Yu VL, Rumans LW, Yee RB: Susceptibility of Pseudomonas maltophilia to antimicrobial agents, singly and in combination. Antimicrobial Agents and Chemotherapy 1979, 16: 833-837.
9. Poulos CD, Matsumura SO, Willey BM, Low DE, McGeer A: In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrobial Agents and Chemotherapy 1995, 39: 2220-2223.
10. Chow AW, Wong J, Bartlett KH: Synergistic interactions of ciprofloxacin and extended-spectrum β-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia. Antimicrobial Agents and Chemotherapy 1988, 32: 782-784.
11. Yu VL, Felegie TR Yee RB, Pasculle AW, Taylor FH: Synergistic interactions in vitro with use of three antibiotics simultaneously against Pseudomonas maltophilia. Journal of Infectious Diseases 1980, 142: 602-607.
12. Rosenblatt JE, Stewart PR: Combined activity of sulfamethoxazole, trimethoprim and polymyxin B against gram-negative bacilli. Antimicrobial Agents and Chemotherapy 1974, 6: 84-92.
13. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3. NCCLS, Villanova, PA, 1994.
14. Vartivarian SE, Anaissie E, Bodey G, Sprigg H, Rolston K: A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy, Antimicrobial Agents and Chemotherapy 1994, 38: 624-627.